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Activation of MAPK signaling via BRAF mutations may limit the activity of EGFR inhibitors in EGFR-mutant lung cancer patients.
However, the impact of BRAF mutations on the selection and fitness of emerging resistant clones during anti-EGFR therapy remains
elusive. We tracked the evolution of subclonal mutations by whole-exome sequencing and performed clonal analyses of individual
metastases during therapy. Complementary functional analyses of polyclonal EGFR-mutant cell pools showed a dose-dependent
enrichment of BRAFV600E and a loss of EGFR inhibitor susceptibility. The clones remain stable and become vulnerable to combined
EGFR, RAF, and MEK inhibition. Moreover, only osimertinib/trametinib combination treatment, but not monotherapy with either of
these drugs, leads to robust tumor shrinkage in EGFR-driven xenograft models harboring BRAFV600E mutations. These data provide
insights into the dynamics of clonal evolution of EGFR-mutant tumors and the therapeutic implications of BRAF co-mutations that
may facilitate the development of treatment strategies to improve the prognosis of these patients.
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INTRODUCTION
Targeted treatment of epidermal growth factor receptor (EGFR)-
mutant non-small cell lung cancer (NSCLC) is a landmark for
rational therapy addressing molecular vulnerabilities1. Treatment
with first- and second-generation EGFR tyrosine kinase inhibitors
(TKIs) markedly improved the clinical outcome of patients with
advanced EGFR-mutant NSCLC2–5. Currently, osimertinib is the
only third-generation EGFR inhibitor approved for the sequential
treatment of patients with acquired EGFRT790M resistance mutation
occurring after first- and second-generation TKIs6,7. In addition,
osimertinib became the new standard-of-care in the first-line
treatment of patients with EGFR-mutant NSCLC8,9.
Despite the clinical efficacy of osimertinib in the first- and
second-line treatment of EGFR-mutant NSCLC, drug resistance
with disease progression is inevitable10–18. Various EGFR-depen-
dent and EGFR-independent resistance mechanisms have been
identified including EGFRC797S and EGFRG724S mutations, MET/HER2
amplification, activation of the RAS–mitogen-activated protein
kinase (MAPK) or RAS–phosphatidylinositol 3-kinase (PI3K) path-
ways, new fusions, and histological transformation. RAS–MAPK
pathway aberrations that are known to confer resistance to
osimertinib include BRAF, NRAS, and KRAS mutations10,19,20. BRAF
mutations occur in 2–4% of NSCLC patients and the vast majority
are localized in the kinase domain, including the most common
mutation BRAFV600E. BRAF mutations can be categorized into three
classes based on their ability to act as monomers or dimers and
based on their kinase activity. BRAFV600E mutations represent class
I mutations that, similarly to class II BRAF mutations (RAS-
independent), result in activation of the BRAF kinase and the
MAPK pathway (gain of function). Class III BRAF mutations (RAS-
dependent) result in an impaired BRAF kinase activity and amplify
ERK signaling depending on upstream activating signals (e. g. RAS
activating mutations, NF1 tumor suppressor deletion)21. All classes
of BRAF mutations are recognized as oncogenic driver mutations,
yet only BRAFV600E mutations represent clinically actionable drug
targets in cancer patients22,23.
BRAFV600E mutations have been identified as a resistance
mechanism to osimertinib in roughly 3% of cases with EGFR-
mutant lung cancer, with or without concurrent EGFRT790M
mutation10,19,20. Several combination therapies have been pro-
posed for BRAF resistance in EGFR-mutant lung cancer, but an
integrated genomic analysis of these tumors is lacking and
precludes an optimization of therapeutic regimen24–27. Further-
more, the current understanding of the clonal evolution of EGFR-
mutant cells that concomitantly acquire BRAF mutations during
anti-EGFR therapy remains limited.
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Within the present study, we aimed for a comprehensive and
translational approach to systematically characterize the role of
co-occurring EGFR/BRAF mutations in patients with advanced lung
adenocarcinoma.
RESULTS
Targeting BRAF-driven resistance in EGFR-mutant lung cancer
To characterize the role of BRAF mutations in the context of
druggable EGFR mutations, data of eligible patients from several
centers were analyzed (see “Methods”). This led to the identifica-
tion of 15 patients with lung adenocarcinoma harboring activating
EGFR mutations and co-occurring BRAF mutations (Fig. 1a, Table
1). In five cases, EGFR and BRAF mutations were detected at the
time of initial diagnosis, whereas in ten patients, BRAF mutations
were acquired after anti-EGFR therapy (Table 1). In eight patients,
BRAF mutations occurred after osimertinib treatment, in one
patient after gefitinib treatment, and in one patient after afatinib
treatment. The treatment history of these ten patients before the
detection of acquired BRAF mutations is outlined in Supplemen-
tary Fig. 1. The median duration of time elapsed from diagnosis of
EGFR-mutant lung cancer to the detection of acquired BRAF
mutation was 33.8 months (95% CI: 9.0–99.1 months) (Fig. 1b). Six
patients were evaluable for analysis of subsequent treatment and
outcome after detection of acquired BRAF mutation (Fig. 1c, Table
2). Median overall survival (OS) for these six patients after
detection of BRAF-driven acquired resistance was 7.8 months
(95% CI: 5.1–10.5 months; Fig. 1c). Of which, four patients
(P12–P15) presenting with acquired activating BRAFV600E and
BRAFK601E (gain of function) mutations received either osimertinib
and bevacizumab (n= 2), osimertinib and chemotherapy (n= 1),
or chemotherapy plus bevacizumab (n= 1) as the next line of
treatment after detection of the BRAF mutation (Table 2). In the
Cologne cohort, we detected 26/1951 co-occurrences of EGFR and
BRAF mutations (1.3%) but narrowed it down to clearly activating
EGFR mutations. In the Paris cohort, we detected 4/184 co-
occurrences of EGFR and BRAF mutations (2.2%). Overall, our data
show that BRAF mutations represent a resistance mechanism in a
relevant proportion of EGFR-mutant patients, warranting further
investigation of the underlying clinical and evolutionary dynamics.
Next, we selected two patients (P01, P04) who acquired
BRAFV600E mutation under osimertinib treatment to evaluate the
safety and efficacy of various drug combinations including EGFR,
RAF, MEK, or MET inhibitors, chemotherapy, or bevacizumab
(Table 2, Fig. 1d, Supplementary Fig. 2a). We chose functional
imaging by FDG-PET for (early) metabolic response evaluation
during our investigational conduct (Supplementary Table 1) and
monitored treatment-related adverse events that were predomi-
nantly of low grade and manageable (Supplementary Table 2).
Osimertinib treatment was initiated and carried out for 16 months
in P01 and 7 months in P04 before the detection of progressive
disease. While in P01 EGFRT790M mutation was sustained, in P04,
we observed a loss of EGFRT790M mutation. Both patients started
with dabrafenib and trametinib, which in both cases did not lead
to a confirmed metabolic response. Both patients underwent a
rebiopsy of progressive lesions and started immediately with
osimertinib and dabrafenib. In P01, the rebiopsy revealed an
EGFRdel19 mutation, loss of EGFRT790M, no BRAFV600E mutation and
an intermediate-level MET amplification (GCN 5.58, FISH). Sub-
sequent doublet combinations of osimertinib plus dabrafenib and
afatinib plus crizotinib showed either primary refractory disease or
metabolic responses that could not be confirmed in the next
scans. In contrast, the triple combination of osimertinib, dabrafe-
nib, and trametinib led to a prolonged metabolic response and
clinical benefit (Supplementary Table 1, Table 2). In P04, doublet
combinations of osimertinib and dabrafenib led only to a short
metabolic response not confirmed in the next scan, and with the
addition of trametinib, we then observed a marked metabolic
response in the primary lung tumor but not in the hepatic
metastases. Rebiopsy of the hepatic lesions revealed an EGFRdel19
mutation with T790M and C797S resistance mutations in cis and
no BRAF mutation. Treatment was thus changed to osimertinib
plus chemotherapy/transarterial chemoembolization due to pro-
gressive liver metastases. The patient, unfortunately, died a year
after detection of BRAFV600E resistance. Thus, biopsy-guided
mutational profiling in conjunction with FDG-PET imaging can
guide effective combination therapies to overcome resistance in
these patients.
To investigate the clonal dynamics during the development of
resistance, we performed whole-exome sequencing (WES) of
biopsies from multiple time points and different metastatic sites
obtained from P01 to P04 (Fig. 1d–i (P04), Supplementary Fig. 2
(P01)). For patient P01 WES could be performed on the primary
tumor and two metastatic samples (Supplementary Fig. 2), while
insufficient tissue, unfortunately, precluded analysis of the BRAF-
mutant metastasis. Pairwise clustering based on the cancer cell
fractions of the mutations (CCFs, i.e. frequency of occurrence in
cancer cells after adjustment for purity, ploidy, and copy number
(CN)28 revealed a high proportion of private mutations, while only
a few mutations (e.g., EGFRdel19) were clonal in all samples
(Supplementary Fig. 2b–d). Due to the sequencing quality, an
intra-biopsy heterogeneity analysis was not undertaken, but
phylogenetic tree analysis between biopsies indicated a branched
evolution during resistance development (Supplementary Fig. 2e).
Interestingly, a common ancestor gave rise to the pleural upper
lung lobe metastasis and clones subsequently developing into the
pleural metastasis and the primary tumor. In accordance with this
branching model, the CN profiles show shared alterations
between all three available samples, but also CN segments
exclusive to just one or a pair of samples (Supplementary Fig. 2f).
Our data indicate early branching during tumor development and
is in accordance with a scenario where resistant cells develop in
parallel to the primary tumor even before treatment pressure is
applied.
For patient P04 WES was performed on a peritoneal metastasis
that occurred during initial inhibitor treatment (EGFRdel19 and
EGFRT790M), a liver metastasis 6 months after treatment had been
switched to osimertinib (EGFRdel19 and BRAFV600E) and a rebiopsy of
the same liver lesion at progressive disease under dabrafenib and
trametinib treatment (EGFRdel19 and BRAFV600E) (Fig. 1d). Compara-
tive pairwise CCF-based clustering showed only a few mutations
to be shared between the peritoneal biopsy and the first liver
biopsy (e.g., EGFRdel19), while the majority was private for each one
of metastases (e.g., EGFRT790M and BRAFV600E, respectively) (Fig. 1e).
In contrast, almost all mutations were found to be shared between
both biopsies of the liver lesion (Fig. 1f). Subclonal composition
analysis of the peritoneal metastasis revealed two subclones (C1
60%, C3 40%), while the liver metastases presented with one
dominant clone each (Fig. 1g).
For subsequent phylogenetic analyses, a founder clone C0 was
derived based on the mutations shared by all biopsies since the
material of the primary tumor was unavailable for WES. Tracking
the genomic development from C0 indicated a branched
evolution diverging towards the peritoneal metastasis carrying
EGFRT790M with its first subclone C1, which further spawned a new
subclone C3 present in the same biopsy (Fig. 1h). The liver
metastasis appeared to have developed from C0 independently of
the peritoneal metastasis by acquiring the BRAFV600E mutation
(C2). The rebiopsy of that lesion showed a distinguishable clone
C4 which only carried one additional non-synonymous mutation
of unknown biological relevance indicating a high degree of
genetic similarity (Fig. 1h). In addition, genetic similarities between
lesions were quantified to gain further insight into the clonal
evolution toward therapy resistance (see Supplementary Material
for further details). This analysis supports a branched evolution
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Fig. 1 Clinicopathological characteristics for the study cohort and clonal evolution. a Spectrum and distribution of BRAF co-mutations in
patients with EGFR-mutant lung adenocarcinoma. b Kaplan–Meier curve of the time elapsed from the detection of the EGFRmutation until the
detection of the acquired BRAF mutation (as events) in days. c Kaplan–Meier curve of overall survival for patients P01, P04, P12–P15 that were
available for survival analysis. d Overview of the biopsies and key molecular findings by NGS for patient P04. Flow chart (top right) summarizes
lines of therapy approaches overtime after the acquisition of BRAFV600E mutation. e, f Clustering of WES-derived mutations based on their CCFs
between pairs of tumor biopsies to detect clusters of shared clonal and private mutations. Candidate mutations in EGFR and BRAF are
highlighted. g Subclonal composition in individual biopsies indicating two subclones (C1, C3) in the peritoneal metastasis and single clones in
the liver metastases. h Clonal evolution of reconstructed cell populations presented as a phylogenetic tree. The computationally inferred most
common ancestor C0 is common to all subsequent clones and highlighted mutations are present in descendent clones. (i) Visualization of
evolutionary genetic distances between normal tissue and longitudinal biopsies. WES whole-exome sequencing, NGS next-generation
sequencing, PD progressive disease, PR partial response, D+ T dabrafenib+trametinib, O+D(+ T) osimertinib+dabrafenib(+trametinib), O
+ CTX+ B osimertinib+chemotherapy+bevacizumab, O + Tc TACE osimertinib+transarterial chemoembolization, C clone, CCF cancer cell
fraction.
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Table 1. Clinicopathological characteristics for the study cohort.
Patient ID Sex Age Biopsy EGFR mutation BRAF mutation Co-mutations
01 F 70 TB E746_A750del, T790M V600E Class I Acquired
(osimertinib)
Persistent T790M
02 F 71 TB E746_A750del, T790M S605C Not classified Initial TP53 R273H
03 M 61 TB L858R K601E Class II Initial DDR2 R279M
04 M 72 TB E746_A750del, T790M V600E Class I Acquired
(osimertinib)
loss of T790M
05 M 77 TB L861Q G466A Class III Acquired (afatinib) ERBB2 G815A, TP53 S166*
06 M 66 TB L858R, V834L V600E Class I Acquired
(osimertinib)
loss of EGFR mutations
07 F 84 TB L858R V600E Class I Initial –
08 F 74 TB L858R G466E Class III Acquired (gefitinib) –
09 M 50 TB E746_A750del V600E Class I Acquired
(osimertinib)
CCDC6-RET
10 F 67 TB L747_P753delinsS G466E Class III Initial KRAS A59E
11 F 75 TB E746_A750del S605N Not classified Initial –
12 F 61 LB E746_A750del, 790M, C797S, C797G V600E Class I Acquired
(osimertinib)
TP53 splice
13 M 50 LB L747_S752del K601E Class II Acquired
(osimertinib)
TP53 R248G
14 F 70 TB L858R, T790M, C797S V600E Class I Acquired
(osimertinib)
TP53 K120E, BRCA S237Y (VUS)




Patients with lung adenocarcinoma harboring activating EGFR mutations and co-occurring BRAF mutations were collected from three different cancer centers.
Class I and class II (RAS-independent) BRAF mutations result in activation of the BRAF kinase and the MAPK pathway. Class III (RAS-dependent) BRAF mutations
result in impaired BRAF kinase activity and amplify ERK signaling based upon upstream activating signals. BRAFS605C/N mutations (variants) lie within the kinase
domain of the BRAF protein, they are not yet functionally classified. TB tissue biopsy, LB liquid biopsy.
Table 2. Systemic treatment lines and outcome evaluable for six patients after detection of the acquired BRAF mutation.
Patient ID BRAF mutation Time to detection of BRAF mutation
after diagnosis (months)
Treatment after detection of BRAF mutation TTD (days) OS (days) Outcome
01 V600E (Class I) 96 Dabrafenib+trametinib (1 L) 74 636 Alive
Osimertinib+dabrafenib (2 L) 27
Afatinib+crizotinib (3 L) 65
Osimertinib+dabrafenib+ (4 L) trametinib 288
Osimertinib+bevacizumab (5 L) 53
Afatinib+crizotinib (6 L) 105
Osimertinib+dabrafenib+ (7 L) trametinib na
04 V600E (Class I) 47 Dabrafenib+trametinib (1 L) 38 287 Deceased
Osimertinib+dabrafenib (2 L) 93
Osimertinib+dabrafenib+ (3 L) trametinib 77




12 V600E (Class I) 38 Carboplatin+paclitaxel+ (1 L) bevacizumab 68 101 Deceased
13 K601E (Class II) 26 Osimertinib+paclitaxel (1 L) 50 239 Deceased
14 V600E (Class I) 34 Osimertinib+bevacizumab (1 L), carboplatin
+gemcitabine (2 L)
92, 40 359 Deceased
15 V600E (Class I) 51 Osimertinib+bevacizumab (1 L) carboplatin
+paclitaxel+ (2 L) bevacizumab
57, 163 219 Deceased
BRAFV600E and BRAFK601E mutations result in an increased BRAF kinase activity. See also Fig. 1c for the Kaplan–Meier curve of OS. TTD time-to-treatment
discontinuation, OS overall survival: time from acquired resistance (date of biopsy) until death/last day of follow-up, TACE transarterial chemoembolization.
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trajectory model with a common ancestor giving rise to the
peritoneal metastasis and liver metastases (Fig. 1i). While the
peritoneal metastasis and liver metastases are not closely related,
only minor changes occurred between the first and second biopsy
of the liver lesion (Fig. 1i). Accordingly, the CN landscape is very
similar between the peritoneal metastasis and liver metastases,
but almost identical between both liver biopsies (Supplementary
Fig. 3). This highlights that the different metastases and resistance
mechanisms (EGFRT790M and BRAFV600E, respectively) developed
independently from a common ancestral clone rather than in a
linear relationship. Also, the remarkably high similarity between
both liver biopsies indicates that selection pressure did not give
rise to a highly distinct new subclone, potentially due to the lack
of an EGFR inhibitor in the combination treatment. However, it
may also be due to resistance to anti-BRAF therapy already being
present in the clone C2 that propagates to C4 or may have a non-
genomic basis not detectable by WES.
For a third patient (P14) we obtained a biopsy at the time of
progression under osimertinib treatment (Supplementary Fig. 4a).
WES of this biopsy showed the presence of several oncogenic
EGFR mutations, namely L858R, T790M, and C797S (Supplemen-
tary Fig. 4b). All of those mutations were clonal, the T790M and
C797S mutations are in agreement with previously described
resistance mechanisms to EGFR inhibitors. Interestingly, we also
detected a BRAFV600E mutation (Supplementary Fig. 4b, Table 1). In
contrast to the EGFR mutations, the BRAF mutation was subclonal
and may thus indicate the branching of a newly developing
subclone. This further highlights the complexity of disease
resistance, which may incorporate several mechanisms of
resistance development in parallel. Overall, the clonal analyses
highlight that a process of branched evolution underlies
resistance to targeted treatments in patients with EGFR-mutant
tumors and may give rise to various independent resistance
mechanisms.
Resistance through the selection of BRAFV600E-positive clones
To functionally validate our clinical observations, we over-
expressed BRAFV600E in EGFRdel19-mutant PC9 cells. To compare
BRAFV600E-mediated effects to upstream activation of MAPK
signaling, we generated cells expressing NRASQ61K, a mutation
reported in preclinical models of acquired EGFR-inhibitor resis-
tance16,19. In a polyclonal pool of PC9 cells stably expressing
BRAFV600E or NRASQ61K, only modest activation of the MAPK
signaling was detected as determined by immunoblotting of
phospho-ERK (Fig. 2a). However, residual phospho-ERK-levels after
osimertinib treatment were detected only in cells with BRAFV600E
or NRASQ61K overexpression but not in control PC9 empty vector
(EV) cells. During 7-14 day treatment the insufficient inhibition of
MAPK signaling translated into the outgrowth of osimertinib-
resistant clones in cells expressing BRAFV600E or NRASQ61K (Fig. 2b,
c). In line with this observation, only ≤0.3% of PC9 (EV) cells were
found to be able to give rise to colonies during increasing doses of
osimertinib treatment (Fig. 2d). However, overexpression of
BRAFV600E or NRASQ61K significantly enhanced the pool of cells
with the capacity to outgrow during therapy to 5.2% (BRAF) and
4.5% (NRAS) or less in a dose-dependent manner (Fig. 2d).
The next question was whether the enrichment of cells with
high BRAFV600E or NRASQ61K expression would have an impact on
EGFR inhibitor sensitivity. Therefore, polyclonal PC9BRAF-V600E and
PC9NRAS-Q61K cells were preselected either with 10 nM (PC9BRAF/
NRAS OS 10 nM) or 100 nM (PC9BRAF/NRAS OS 100 nM) of osimertinib
over the course of >30 days. Using RT-PCR a dose-dependent
elevation of RNA levels of the respective resistance alleles was
found in PC9BRAF OS and PC9NRAS OS cells after osimertinib
selection (Fig. 2e, f). Osimertinib-preselected cells exhibited a
higher induction of BRAFV600E expression (9.39-fold) than NRASQ61K
expression (4.25-fold, p= 0.036). Accordingly, untreated
osimertinib-preselected cells with high BRAFV600E expression
displayed stronger phospho-ERK staining when compared to
NRASQ61K (Fig. 2g). Both osimertinib-preselected PC9BRAF-V600E and
PC9NRAS-Q61K cells showed higher levels of sustained phospho-ERK
during osimertinib treatment (Fig. 2g) and a higher degree of
resistance in viability assays compared to non-selected cells (Fig.
2h). A similar degree of resistance was observed against the EGFR
inhibitors erlotinib or afatinib (Supplementary Fig. 5a, b) but not
against the non-specific, chemotherapeutic cisplatin (Supplemen-
tary Fig. 5c).
To further substantiate our data in an independent model,
BRAFV600E was overexpressed in the EGFRdel19-mutant HCC827 cell
line. Again, a dose-dependent induction of resistance thro
ugh osimertinib-preselection was observed in polyclonal
HCC827BRAF-V600E cell pools (Supplementary Fig. 5d). These
findings are in line with our clinical observations and previous
cases that identified BRAF-mediated resistance in EGFR-mutant
tumors during anti-EGFR therapy. Our results suggest that BRAF-
mutant clones are enriched through EGFR-directed therapy in
EGFR-mutant adenocarcinoma.
Overcoming BRAFV600E-mediated resistance in EGFR-mutant
cells
Previous studies have found that concomitant KRAS and EGFR
mutations may increase the cell death rate of adenocarcinoma
cells through hyperactivation of ERK signaling29,30. We tested
whether the activation of MAPK signaling via BRAFV600E may have
a similar effect in EGFR-mutant PC9 cells. To this end, the cell
proliferation of PC9BRAF-V600E and PC9NRAS-Q61K was measured over
5 days, but no major differences were observed compared to EV
cells (Fig. 3a). We also did not detect any differences in the basal
cell death rate between cell lines (Supplementary Fig. 6a).
Consequently, cells with high expression of mutant BRAF/NRAS
did not get counter-selected after the withdrawal of osimertinib
(Fig. 3b, c).
Next, we tested combination therapies by targeting EGFR and
MAPK signaling individually in PC9BRAF-V600E and PC9NRAS-Q61K cells
(Fig. 3d). Both MEK inhibition and BRAF inhibition, as mono-
therapy, had a limited effect on the viability of PC9BRAF-V600E
mutant cells (Supplementary Fig. 6b, c). In contrast, the combina-
tion of osimertinib and MEK or BRAF inhibition effectively
prevented the outgrowth of colonies (Fig. 3d). To further validate
our previous findings on a transcriptional level, we performed RNA
sequencing of PC9 (EV), PC9BRAF-V600E, and PC9BRAF-V600E OS
100 nM cells treated with osimertinib, trametinib, a combination
of both or control for 48 h (see Supplementary Material). As
expected, a principal component analysis showed that osimertinib
monotherapy had strong effects only on PC9BRAF-V600E cells, while
trametinib plus osimertinib comparably impacted both PC9BRAF-
V600E and PC9BRAF-V600E OS 100 nM cells (Supplementary Fig. 6d).
We next clustered samples based on the expression of E2F target
genes to assess the impact on cell cycle-related gene expression
as a surrogate marker for the cytotoxic effects of the given
perturbation (Fig. 3e). In this analysis, the strongest down-
regulation of E2F genes was present in the group of cell line/
treatment combinations that led to reduced cell numbers in
crystal violet assays (Fig. 3d). Repression of E2F target genes was
lower in unselected PC9BRAF-V600E cells with osimertinib compared
to PC9 EV cells or compared to combination treatment (Fig. 3d).
This indicates the limited efficacy of osimertinib monotherapy
treatment if a BRAF mutation is present even without prior
selection and supports the use of combination treatment.
Furthermore, in PC9BRAF-V600E OS 100 nM cells the expression of
MAPK pathway responsive genes was only perturbed during
osimertinib and trametinib treatment (Supplementary Fig. 7a)31.
Next, we assessed the synergy between osimertinib and
trametinib, using ZIP-based synergy analysis, and found a strong
D Schaufler et al.
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synergy that correlated with the expression of BRAF-V600E in PC9
cells (Fig. 3f, see Methods). The calculated synergy score for
osimertinib and vemurafenib was limited and we found an
antagonism for the combination of trametinib and vemurafenib
inhibition in PC9BRAF-V600E mutant cells (Supplementary Fig. 7b, c).
Finally, using a three-fold titration matrix, we observed a
considerably low synergy for osimertinib and vemurafenib
treatment compared to osimertinib and trametinib treatment,
which was not further increased in a triple combination by adding
vemurafenib (Supplementary Fig. 7d). In accordance with the
synergy results, osimertinib with trametinib in contrast to
osimertinib alone resulted in full inhibition of phospho-ERK
signaling. Vemurafenib did not fully abrogate the sustained
phospho-ERK signaling, as it also hyperactivated phospho-ERK as
monotherapy, most likely due to the paradoxical effect on the
endogenous wild type BRAF kinase (Fig. 3g)32. To further validate
our in vitro results, we performed an in vivo study with xenografts
implanted with PC9BRAF-V600E cells that were preselected for high
BRAFV600E expression. Once the mice developed tumors, we
started with the treatment regimen consisting of vehicle,
osimertinib, trametinib or the combination of osimertinib and
trametinib for 21 days (Fig. 3h). Compared to vehicle treatment,
trametinib did not significantly decrease tumor volume, and
osimertinib monotherapy led to a measurable tumor growth
reduction. However, only, combination therapy led to robust
tumor shrinkage in these xenografts (Fig. 3h). Thus, our in vivo
data largely reflects our in vitro findings and suggests that
combination therapy is necessary to induce substantial tumor
shrinkage in tumors harboring activating EGFR and BRAF muta-
tions. Of importance, none of the mice in the individual treatment
arms experienced weight loss (Supplementary Fig. 7e) or any
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Fig. 2 Selection of BRAFV600E-positive clones in EGFR-mutant cells. a Immunoblotting of PC9 cells expressing the annotated constructs,
treated with (+) or without (−) osimertinib (48 h). Hsp90 is used as a loading control. b Clonogenicity assays of PC9 derived cell lines treated
with osimertinib for 7 and 14 days or DMSO control for 7 days are displayed. c Quantitative analysis of (b) normalized to PC9 (EV). d Limited
dilution assay of PC9-derived cell lines treated for 21 days before analysis. e, f qRT-PCR analysis of mRNA expression in e BRAF and f NRAS in
PC9 derived cell lines normalized to EV. g Immunoblotting of PC9 cells expressing the annotated constructs that were treated as in (a).
h Viability curves of PC9 cells expressing the annotated constructs treated with osimertinib (72 h) are shown. The relative area under the curve
(AUC) in % compared to a theoretical non-responding AUC. Error bars indicate mean ± SD. Two-tailed paired t tests, ***p < 0.001, **p < 0.01,
*p ≤ 0.05, n.s.p > 0.05. EGFR epidermal growth factor receptor, BRAF B-rapidly accelerated fibrosarcoma, NRAS neuroblastoma rat sarcoma, EV
empty vector.
D Schaufler et al.
6
npj Precision Oncology (2021)   102 Published in partnership with The Hormel Institute, University of Minnesota
DISCUSSION
Osimertinib replaced other EGFR inhibitors in the early lines of
therapy. This development had a major impact on the resistance
profiles and development of effective salvage therapies10–15,18,33.
The activation of MAPK signaling seems to play a more prominent
role in patients' progressive on third-generation EGFR inhibitors
when compared to first- and second-generation EGFR inhibi-
tors11,16,19,20,34. Our comprehensive genomics study of EGFR-
mutant patients with co-occurring BRAF mutations provides
insights into the evolution of MAPK-driven resistance and its
impact on EGFR-directed treatment.
Our combination of longitudinal clinical and genomic analyses
provides insight into the subclonal heterogeneity of the individual
tumors and corresponding metastases during resistance evolu-
tion. Our clonality analyses revealed that resistance to osimertinib
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combination of dabrafenib plus trametinib (initiated at detection
of BRAFV600E mutation) was driven by an evolutionary branching
process rather than a linear trajectory of one clone that continues
to acquire additional resistance mutations. Moreover, in both
patients, the different metastases are genetically distinct from
each other but arise from common ancestors that do not carry a
resistance mutation. Even within our limited cohort, we observe
different patterns of clonal evolution: while for P04 a common
ancestor most likely from the primary tumor gave rise to the
different metastases, for patient P01 phylogenetic analyses are in
accordance with a model supporting much earlier branching. Of
note, resistance mutations such as EGFRT790M and BRAFV600E were
not detected by either panel sequencing or WES in samples still
sensitive to the respective inhibitors. This may indicate that they
developed either de novo during treatment or were pre-existent,
but at a frequency to low to be detected without selection
pressure.
Overall, our results demonstrate the presence and further
development of tumor heterogeneity that can give rise to multiple
resistance mechanisms due to treatment selection pressure.
Moreover, our genomic analysis emphasizes that we are faced
with a complex mutational landscape based on intra-tumoral,
inter-tumoral, and inter-patient heterogeneity. It thus constitutes a
major clinical challenge for the development of an efficient
treatment strategy to counteract tumor progression. Based on the
present findings a diagnostic strategy aiming to address the
multilayered heterogeneity e.g. using liquid biopsies or multiple
re-biopsies appears warranted to optimize treatment schedules.
Our data suggest that one promising treatment strategy for
patients with concurrent EGFR and MAPK pathway activation may
require alternating treatment regimens with intermittent changes
between drug combinations based upon observed heterogenic
tumor response and emerging resistance patterns. To facilitate
this strategy FDG-PET can be quite useful for rapid treatment
evaluation and hence, dynamic clinical management as demon-
strated by our investigational approach. However, we are aware
that more patients need to be profiled in the future to
compliment our results.
We and others have previously found that acquired resistance
through activation of MAPK signaling via KRAS mutations can be
detected in patients receiving third-generation EGFR inhibi-
tors11,12. BRAF mutations and BRAF rearrangements have also
been shown to play a similar role like KRAS in the resistance
setting of EGFR-mutant adenocarcinoma16,19,34. This is surprising
as previous functional analyses indicated that mutant KRAS
mutations may augment the cell death rate of EGFR-mutant cells
and thereby limit the outgrowth of resistant clones29. Our cell line
models indicate that concomitant MAPK pathway signaling is
tolerated when BRAF or NRAS are activated. This corresponds with
our clinical observation that BRAF mutations can co-occur with
EGFR mutations even before anti-EGFR therapy. Interestingly, the
levels of phospho-ERK activation differ strongly between BRAF-
and NRAS-mutant cells but we did not observe major differences
in the ability of these alleles to promote resistance or cell death in
EGFR-mutant cells. These functional observations are also in line
with our finding that BRAF/EGFR-mutant lung tumors are
recurrently found across different cancer centers, indicating a
basis for the co-existence of BRAF/EGFR mutations without
selection pressure. Future studies are required to fully decipher
the potential differences between MAPK signaling activation at
different levels of the pathway in the context of EGFR-mutant lung
adenocarcinoma. Nevertheless, our in vitro and in vivo findings
fully support the notion that EGFR/MEK combination might be a
viable option to overcome BRAF-driven resistance in patients with
EGFR-mutant lung adenocarcinoma.
In summary, our data uncover basic principles of drug-induced
evolutionary paths underlying BRAF-driven resistance in patients
with lung adenocarcinoma. The integrated analyses support a
model in which concomitant activation of EGFR and BRAF is
selected through anti-EGFR therapy that combines well with EGFR,
BRAF, and MEK inhibitors to overcome resistance. Our systematic
exploration of clinically relevant drug combinations may offer
additional avenues for follow-up investigations into novel




We compiled a cohort of 15 patients with lung adenocarcinoma and
activating EGFRmutations that harbored co-occurring BRAFmutations with
and without prior anti-EGFR treatment. Patients were identified within the
Network Genomic Medicine (NGM) Lung Cancer in Cologne, Germany,
Institute Gustave Roussy in Paris, France, and Cantonal Hospital of Lucerne,
Switzerland. Treatment, genetic findings, and survival of these patients
were evaluated. All patients consented to be analyzed. The study was
conducted in concordance with local ethical guidelines and was reviewed
by the institutional ethics committee. Selected patients were treated with
different lines of therapy including combinations of osimertinib, dabrafe-
nib, and trametinib. These patients provided written informed consent for
a prospective investigational molecular- and imaging-guided personalized
treatment approach. Rebiopsies were acquired at disease progression.
Tissue biopsy was performed through core needle biopsy according to
local standard procedures. Survival of all patients was calculated using the
Kaplan Meier method.
Molecular analyses
The vast majority of the specimens analyzed in our study consisted of tumor
tissue (n= 13). For two patients, liquid biopsies were evaluated. (Table 1).
Next-generation sequencing (NGS)-based molecular profiling was performed
for each patient either on tumor tissue or on circulating tumor DNA (ctDNA).
For patients, P01 and P04 whole-exome sequencing was additionally
performed on the tumor tissue. For patients P01 and P04, we obtained
longitudinally serial repeated tissue biopsies of the leading tumor lesions at
each time of progression during treatment with different combinations of
osimertinib, dabrafenib and trametinib, and other therapies. NGS of tumor
tissue was performed as previously described35–38. Plasma analysis of ctDNA
was performed as previously reported39.
Fig. 3 Overcoming BRAFV600E-mediated resistance in EGFR-mutant cells. a Growth series of PC9 derived cell lines counted for 5 days every
24 h (see Methods). b Immunoblotting of PC9BRAF-V600E OS 100 nM, PC9NRAS-Q61K OS 100 nM, and PC9 (EV). Osimertinib-preselected cells were
cultured for 0, 7, and 21 days without osimertinib treatment and plated 48 h before lysis. c Cell viability assay of PC9 cells expressing the
annotated constructs treated for 72 h with osimertinib is shown. The relative AUC (see Methods) of BRAFV600E OS 100 nM and NRASQ61K OS
100 nM after osimertinib withdrawal for >40 days are shown. d Clonogenicity assay of PC9 cells expressing the annotated constructs treated
for 14 days with indicated compounds before staining. e RNA-seq based expression of E2F gene set genes (rows) in PC9 derived cell lines
(columns) after 48 h treatment with indicated inhibitors. Expression was normalized as z-score per gene. f Synergy screen of osimertinib and
trametinib combination treatment in PC9 derived cell lines for 72 h are displayed. g Immunoblotting of PC9 cells expressing the annotated
constructs is shown. Treatment with indicated compounds 48 h before lysis. h Relative tumor volume of xenograft mice injected with PC9BRAF-
V600E OS 100 nM cells in % compared to day 0 of the treatment regimen (see Methods). Error bars indicate mean ± SD. Two-tailed paired t tests
(all except (h); two-tailed Welch’s t tests with Bonferonni-correction), ***p < 0.001, **p < 0.01, *p < 0.05, n.s.p > 0.05. EGFR epidermal growth
factor receptor, BRAF B-rapidly accelerated fibrosarcoma, NRAS neuroblastoma rat sarcoma, EV empty vector.
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PET-CT assessments
The efficacy of treatment was evaluated by positron emission tomography
(PET)/computed tomography (CT) scans using radiolabeled 18F-2-fluoro-2-
deoxy-D-glucose (FDG). Scans were acquired at baseline, and as early as
2 weeks (early assessment) and again at regular intervals roughly every 6
or more weeks (late assessments) after initiation or change of therapy to
capture early metabolic response (measured by standard uptake value
(SUV)max) and morphologic response over time. Scans were conducted as
previously described and performed on a Biograph mCT Flow-Edge 128
PET/CT-system (Siemens Medical Solutions) with a 128-slice spiral CT
component from the base of the skull to the mid-thigh40. We followed
Positron Emission Response Criteria in Solid Tumors version 1.0 guidelines,
assuming that response is characterized by an SUV reduction of at least
30% in the hottest lesion41.
Whole-exome sequencing (WES)
WES was performed on FFPE-derived DNA from serial tumor tissue
rebiopsies obtained at the time of tumor progression during treatment of
patients P01 and P04. In addition, for one patient DNA was extracted from
the primary tumor using the truXTRAC FFPE DNA extraction kit (Covaris,
USA, Cat. No. 520307). Exomes were individually prepared using 200 ng of
DNA using standard protocol SureSelectXT Automated Target Enrichment
for Illumina Paired-End Multiplexed Sequencing and Agilent Bravo
automated liquid handling platform. As for patient P14, there was only a
post-osimertinib tumor biopsy available for WES, which was enriched using
the Agilent SureSelect CR kit (Agilent, USA). After validation (2200
TapeStation, Agilent Technologies) and quantification (Qubit System,
Invitrogen, Waltham, USA) pools of libraries were generated. The pools
were quantified using the KAPA Library Quantification kit (Peqlab,
Germany, KAPBKK4854) and 7900HT Sequence Detection System (Applied
Biosystems, Waltham, USA) and subsequently sequenced at 140× mean
coverage on an Illumina NovaSeq6000 sequencing instrument using a
paired-end 2 × 100 bp protocol.
WES and clonality analysis
Analysis of raw sequencing data and clonality analyses were performed
using an established pipeline42: After alignment of the raw sequencing
data to the hg19 reference genome in total 137–325 million reads could
successfully be mapped per sample corresponding to a mean coverage of
93×–200× per sample and covering all intended exonic target region with
≥20× coverage for 90–98% of those. In summary, of the 42.3 megabases of
exonic regions as defined by the GRCh 37/hg19 RefSeq genome
annotation, 39–40 megabases of exons were sufficiently covered for
mutation calling and subsequent analyses. Thus, allelic fractions of somatic
mutations were corrected for purity and CN changes to determine cancer
cell fractions (CCF). The distribution of CCFs was then searched for distinct
subpopulations by using a nonparametric method to deconvolute the
noise in the CCFs. This allows for the identification of genetically distinct
tumor subclones and the reconstruction of tumor evolutionary histories.
Cell culture and functional analyses
Human NSCLC cell lines were verified by STR profiling at the Institute for
Forensic Medicine of the University Hospital of Cologne. PC9, HCC827, and
HEK293T cell lines were obtained from ATCC. PC9 and HCC827 cells and
their osimertinib-preselected derivatives were cultured in RPMI (Fisher
Scientific, USA, Cat. No. 12004997) HEK293T cells were cultured in DMEM
(Fisher Scientific, USA, Cat. No. 61965-026). All media were supplemented
with 10% fetal bovine serum (Fisher Scientific, USA, Cat. No. 10270-106)
and 1% penicillin/streptomycin (Fisher Scientific, USA, Cat. No. 15070-063).
All cells were grown at 37 °C in a humidified atmosphere with 5% CO2.
Reagents
For cell culture studies, osimertinib (LC Laboratories, USA, Cat. No.
1421373-65-0), trametinib (LC Laboratories, USA, Cat. No. 871700-17-3),
and vemurafenib (LC Laboratories, USA, Cat. No. 918504-65-1) were
dissolved in dimethyl sulfoxide (DMSO) (Carl Roth, Germany, Cat. No.
4720.4) to a final stock concentration of 10mM. Cisplatin (pharmacy of
University Hospital of Cologne) was diluted to 3.33mM in 0.9% NaCl.
Crystal violet assay
Totally, 105 cells were plated into one well of a 6-well plate and treated
with DMSO (control), 300 nM osimertinib, 100 nM trametinib, 1 µM
vemurafenib, and combinations osimertinib plus trametinib and osimerti-
nib plus vemurafenib. Seven or 14 days after treatment, cells were fixed in
4% paraformaldehyde (Carl Roth, Germany, Cat. No. CP10.1) in phosphate-
buffered saline (PBS) (Fisher Scientific, USA, Cat. No. 14190144), stained
with 0.1% crystal violet (Sigma Aldrich, USA, Cat. No. C3886-25G) in PBS,
and rinsed in PBS before image acquisition. For quantification, the Crystal
Violet dye was dissolved in 2 ml methanol (Carl Roth, Germany, Cat. No.
CP43.4) in the 6-well plate. Twenty microlitres of this solution were diluted
1:10 with methanol and injected into 96-well plates. The read-out was the
absorption at 560 nm wavelength. The results per cell line were normalized
against their DMSO-controls and then against the empty vector (EV)
control cell line.
Protein overexpression experiments
Vectors pBABE puro, pBABE-puro-BRAFV600E, and pBABE-NRASQ61K were
cotransfected with a helper plasmid into HEK 293T cells using TransIT-LT1
reagent (Mirus, USA, Cat. No. MIR2300). Forty-eight hour post transfection,
replication-incompetent retroviruses were collected from the supernatant
for infection of PC9 and HCC827 in the presence of 8 μg/ml polybrene
(Merck Millipore, USA, Cat. No. TR1003-G). Twenty-four hour after infection,
the growth medium was changed and 3 μg/ml (PC9) or 2 μg/ml (HCC827)
puromycin (Sigma Aldrich, USA, Cat. No. p8833) was added for selection for
7 days. After selection, cells were analyzed for protein expression.
pBABE-puro was a gift from Hartmut Land & Jay Morgenstern & Bob
Weinberg (Addgene plasmid # 1764; RRID:Addgene_1764).
pBabe-Puro-BRAFV600E was a gift from William Hahn (Addgene plasmid #
15269; RRID:Addgene_15269).
pBabe-NRASQ61K was a gift from Channing Der (Addgene plasmid #
12543; RRID:Addgene_12543).
Cell viability screening
To assess cell viability, cells were plated in 96-well plates in triplicates, and
compounds were added at 9 decreasing compound concentrations 24 h
after seeding. Seventy-two hours later, cell viability was measured via Cell
Titer-Glo (CTG) assay (Promega, USA, Cat. No. g7573) and was normalized
to DMSO-treated controls. Resistance in % was calculated as the area
under the curve (AUC), calculated via Gauss’s trapezoid area formula and
then divided by a theoretical non-responding AUC, all calculated in R. Data
are represented as mean ± standard error of the mean and significance
was calculated by paired Student’s t tests.
RNA isolation and qRT-PCR
Totally, 5 × 105 cells were plated into one well of a 6-well plate and
harvested after 24 h. Total RNA was isolated using the RNeasy-kit (Qiagen,
Germany, Cat. No. 74106) according to the manufacturer’s instructions,
including DNAse I digestion (Qiagen, Germany, Cat. No. 79256). In all,
1.5 μg of total RNA was reverse transcribed using Super-script II (Thermo
Fisher Scientific, USA, Cat. No. 18064022) with random hexamer primers.
Quantitative real-time PCR (qPCR) was performed using the QuantStudio 3
Real-Time PCR System (Thermo Fisher Scientific) and Power SYBR Green
PCR Master Mix (Thermo Fisher Scientific, USA, Cat. No. 4309155). Data
were normalized to GAPDH RNA levels and are presented as mean ± SD
and significance was calculated by paired Student’s t tests.
Flow cytometry
Cell lines were seeded into 6-well plates (1 × 105 cells/well). Twenty-four-
hour later Staurosporine (Sigma Aldrich, USA, S4400) or DMSO control was
added to the medium. Twenty-four-hour later supernatant was collected,
cells were trypsinized (Fisher Scientific, USA, Cat. No. 11560626), washed
with ice-cold PBS, and resuspended in antibody-binding buffer (10mM
HEPES pH 7.4 (Fisher Scientific, USA, Cat. No. 15630080), 140mM NaCl;
2.5 mM CaCl2). Cells were stained for Annexin-V (BD Biosciences, USA, Cat.
No. 556420) and 50 µg/mL propidium iodide (Carl Roth, Germany, Cat. No.
CN74). After 20 min of incubation in the dark, samples were analyzed on a
FACS Gallios Flow Cytometer (Beckman Coulter). We used FACS Kaluza
software (Beckman Coulter) to quantify populations. At least 5 × 104 events
were assessed per measurement. All measurements were performed as
duplicates. Gates used can be found in Supplementary Fig. 8. Data are
presented as mean ± SD.
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Immunoblot
Cell lysates were prepared using RIPA buffer supplemented with protease
inhibitors (Complete Mini Protease Inhibitor Cocktail, Roche, Switzerland, Cat.
No. 11836170001). Protein concentration was determined by BCA assay
(Thermo Fisher Scientific, USA, Cat. No. 23225) and equal amounts of protein
(20 µg) were separated on 4–12% Tris-glycine sodium dodecyl sulfate-
polyacrylamide gel electrophoresis gels (Thermo Fisher Scientific, USA, Cat.
No. XP04125BOX) and transferred to PVDF-FL membrane (Sigma Aldrich, USA,
Cat. No. IPFL00010). Membranes were blocked in 5% milk (Carl Roth, Germany,
Cat. No. T145.1) blocking buffer in Tris-buffered saline (TBS), incubated with
primary antibodies, washed, and incubated with fluorescently labeled
secondary antibodies before detection with Odyssey CLx imaging system (LI-
COR Biosciences). Images were processed using the Image Studio Software (LI-
COR Biosciences). Primary antibodies are EGFR (Cell Signaling, USA, Cat. No. CS-
4267), p-EGFR (Cell Signaling, USA, Cat. No. CS-3777), BRAF-V600E (Spring
Bioscience, USA, Cat. No. E-19290), BRAF (Santa Cruz Biotechnology, USA, Cat.
No. SC-5284), ERK (Cell Signaling, USA, Cat. No. CS-9102), p-ERK (Cell Signaling,
USA, Cat. No. CS-4370), Akt (Cell Signaling, USA, Cat. No. CS-2920), p-Akt (Cell
Signaling, USA, Cat. No. CS-9271) and Hsp90 (Cell Signaling, USA, Cat. No. CS-
4877). All primary antibodies were diluted 1:1000 in 5% milk blocking buffer in
TBS with 0.2% Tween®20 (Sigma Aldrich, USA, Cat. No. P7949-500ML).
Secondary antibodies are goat anti-rabbit 800CW (LI-COR Biosciences, USA,
Cat. No. 926-32211), goat anti-mouse 800CW (LI-COR Biosciences, USA, Cat. No.
926-3220), goat anti-rabbit 680LT (LI-COR Biosciences, USA, Cat. No. #926-
68021), and goat anti-mouse 680LT (LI-COR Biosciences, USA, Cat. No. 926-
68020). All secondary antibodies were diluted 1:20,000 in 2.5% milk blocking
buffer in TBS with 0.2% Tween®20 and 0.01% sodium dodecyl sulfate (SDS)
(Carl Roth, Germany, Cat. No. 8029.4).
All blots derive from the same experiment and were processed in
parallel. Uncropped blots can be found in Supplementary Figs. 9–13.
Synergy screen
Cells were plated in a 6 × 6 wells matrix in 96-well plates. After 24 h cells
were treated with five decreasing concentrations of compound A plus
DMSO control starting from right to left. Cells were also treated at the same
time with five decreasing concentrations of compound B plus DMSO
control starting from the bottom to the top. The topmost left well is only
treated with DMSO, while the bottommost right well is treated with the
highest concentration of both compounds. The following starting
concentrations were used: 300 nM of osimertinib, 100 nM of trametinib,
and 1 µM of vemurafenib. Seventy-two hours after treatment, cell viability
was measured via CTG assay and was normalized to DMSO-treated
controls. Synergy scores were then calculated in R using the SynergyFinder
Package and the Zero Interaction Potency (ZIP) reference model as
implemented in the package. The mean of the nine highest synergy scores
from each matrix is presented ±SD and significance were calculated by
paired Student’s t tests.
3D Synergy screen
Cells were plated as described in “Synergy screen”, just on six plates, each
with a set concentration of vemurafenib to add a third dimension. Cells
were treated for the same time and with the same concentration as in
“Synergy screen”. Cell viability was measured the same way as in “Synergy
screen”. The expected drug combination responses were calculated based
on ZIP reference model using SynergyFinder43. Deviations between
observed and expected responses with positive and negative values
denote synergy and antagonism, respectively.
Growth series
Totally, 1 × 105 cells per well were plated 5 times in triplicates per cell line in
6-well plates. For 5 days, always after 24 h, one triplicate of each cell line was
trypsinized and counted via Z Series Coulter Counter (Beckmann Coulter).
Results were normalized to day 1 and were anticipated from the slope of a
best-fitting line through each data set Data are presented as mean ± SD.
Generating osimertinib selected cell lines
PC9BRAF-V600E, PC9NRAS-Q61K, and HCC827BRAF-V600E cell lines were each
treated with 10 nM or 100 nM osimertinib respectively for >30 days. After
that cells were labeled osimertinib selected (OS) 10 nM or 100 nM,
respectively, and experiments were performed. Even after >30 days
osimertinib treatment in cell culture, cells were continuously kept under
osimertinib treatment.
3′UTR-RNA sequencing
For each cell line (PC9 pBABE EV, PC9 pBABE BRAFV600E, and PC9 pBABE
BRAFV600E OS 100) 5 × 105 cells were plated and left to adhere overnight. The
next day they were treated with 300 nM osimertinib, 100 nM trametinib, a
combination of both, or DMSO control for 48 h. RNA extraction and
sequencing were performed using the Qiagen RNeasy Mini kit following the
manufacturer’s instruction. Totally, 500 ng total RNA were used to prepare 3′
UTR mRNA libraries using the Lexogen QuantSeq kit (Lexogen, Austria, Cat. No.
015.96) according to the standard protocol44. Quality controlled cDNA pools
were quantified with the KAPA Library Quantification kit and sequenced on a
NovaSeq sequencer (Illumina, USA) with a 1 × 100 bp protocol. Raw data were
aligned to the human genome reference GRCh38 using STAR aligner45 and
gene expression was quantified with RSEM46 prior to downstream analysis
with the R package DESeq247. E2F target genes were obtained from the
MSigDB Hallmark collection and MAPK feedback genes from a recently
published MAPK activity score31.
In vivo xenograft model
The local authorities and the animal protection committee approved all
animal procedures of this study.
PC9BRAF-V600E OS100 nM cells (5 × 106) were resuspended in 100 µL PBS
and then inoculated subcutaneously in both flanks of 8- to 12-week-old
female nude mice (RJ:NMRI-FOXN1 NU, Janvier Labs) and treatment was
initiated when tumors reached a mean volume of approximately 50mm3.
Mice were treated daily for 21 days orally with vehicle solution (1% DMSO,
30% PEG300, 0.5% hydroxypropyl methylcellulose, 0.2% Tween-80, ddH2O)
QD, osimertinib (5 mg/kg in 1% DMSO+ 30% PEG300+ ddH2O) QD,
trametinib (1 mg/kg in 0.5% hydroxypropyl methylcellulose, 0.2% Tween-
80, ddH2O) QD or combination (osimertinib as described before and
trametinib as described before) Tumor volumes were measured daily in
two dimensions using a caliper, and the volume was expressed in mm3
using the formula: V= 0.5 × (length × width2), where V is tumor volume,
length is the longest tumor dimension and width is the longest tumor
dimension perpendicular to the length.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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